NSG533 / NSG 533 Exam 1: Advanced Pharmacology
– Wilkes University Actual Exam Complete Questions
& Rationales | Advanced Drug Therapy | Pass
Guaranteed - A+ Graded
Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with renal impairment is prescribed a medication that is
primarily renally excreted. The drug has a half-life of 12 hours in a healthy adult. If this
patient's renal function is reduced by 50%, how will the pharmacokinetics of the drug
most likely be affected?
A. The absorption rate will increase significantly.
B. The volume of distribution will decrease.
C. The half-life will be prolonged, increasing the risk of accumulation.
D. The protein binding will increase, making the drug less effective.
Correct Answer: C
Rationale: The best answer is C because renal excretion is a major route of elimination;
when renal function declines, clearance drops, causing the drug to stay in the body
longer (prolonged half-life) and accumulate to toxic levels.
Q2: Scenario: You are treating a patient with a infection requiring a bactericidal
antibiotic. You explain to the student that the drug's efficacy depends on the time the
free drug concentration remains above the Minimum Inhibitory Concentration (MIC).
Which pharmacodynamic parameter is most critical for prescribing this specific
antibiotic?
A. Peak concentration/MIC ratio
B. Area under the curve/MIC ratio
C. Time above MIC (T>MIC)
D. Post-antibiotic effect
Correct Answer: C
Rationale: This aligns with the pharmacodynamic principle for time-dependent killers
like beta-lactams; the goal is to keep the drug level above the MIC for a certain
percentage of the dosing interval, rather than just relying on a high peak.
Q3: You are comparing two drugs in the same class used for hypertension. Drug A
requires a dose of 10mg to achieve the desired effect, while Drug B requires 100mg.
Which term best describes this difference?
, A. Drug A has higher efficacy than Drug B.
B. Drug B has higher potency than Drug A.
C. Drug A has higher potency than Drug B.
D. Drug B has a better therapeutic index.
Correct Answer: C
Rationale: The best answer is C because potency refers to the amount of drug needed
to produce an effect; since Drug A needs a lower dose to achieve the same effect, it is
more potent, though both may have equal efficacy (max effect).
Q4: A patient is taking a drug that is a "competitive agonist" at a receptor. If the patient
takes an overdose of this drug, what is the most appropriate pharmacological
intervention?
A. Administer a non-competitive antagonist to permanently block the receptor.
B. Administer a competitive antagonist to compete for the receptor site.
C. Increase the dose of the agonist to saturate all receptors.
D. Administer an inducer of the enzyme that metabolizes the drug.
Correct Answer: B
Rationale: In practice, you would administer a competitive antagonist because it
competes with the agonist for the receptor site; as the antagonist concentration rises, it
displaces the agonist, reversing the effect.
Q5: Which scenario best describes the concept of "first-pass effect"?
A. A drug injected intravenously bypasses the liver initially.
B. An orally administered drug is metabolized by the liver before reaching systemic
circulation, reducing bioavailability.
C. A drug is distributed to high-blood-flow organs like the brain and heart first.
D. A drug is excreted by the kidneys before it can be absorbed in the stomach.
Correct Answer: B
Rationale: The best answer is B because the first-pass effect specifically refers to the
metabolism of an oral drug by the liver (via the portal vein) before it enters the general
circulation, significantly lowering the amount of active drug available.
Q6: A patient with a history of angina is prescribed a nitroglycerin patch. What is the
primary mechanism of action that leads to therapeutic vasodilation?
A. Blockade of calcium channels in vascular smooth muscle.
B. Release of nitric oxide (NO), which increases cGMP and relaxes smooth muscle.
C. Inhibition of the conversion of Angiotensin I to Angiotensin II.
D. Direct stimulation of beta-2 receptors in the bronchioles.
Correct Answer: B
– Wilkes University Actual Exam Complete Questions
& Rationales | Advanced Drug Therapy | Pass
Guaranteed - A+ Graded
Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with renal impairment is prescribed a medication that is
primarily renally excreted. The drug has a half-life of 12 hours in a healthy adult. If this
patient's renal function is reduced by 50%, how will the pharmacokinetics of the drug
most likely be affected?
A. The absorption rate will increase significantly.
B. The volume of distribution will decrease.
C. The half-life will be prolonged, increasing the risk of accumulation.
D. The protein binding will increase, making the drug less effective.
Correct Answer: C
Rationale: The best answer is C because renal excretion is a major route of elimination;
when renal function declines, clearance drops, causing the drug to stay in the body
longer (prolonged half-life) and accumulate to toxic levels.
Q2: Scenario: You are treating a patient with a infection requiring a bactericidal
antibiotic. You explain to the student that the drug's efficacy depends on the time the
free drug concentration remains above the Minimum Inhibitory Concentration (MIC).
Which pharmacodynamic parameter is most critical for prescribing this specific
antibiotic?
A. Peak concentration/MIC ratio
B. Area under the curve/MIC ratio
C. Time above MIC (T>MIC)
D. Post-antibiotic effect
Correct Answer: C
Rationale: This aligns with the pharmacodynamic principle for time-dependent killers
like beta-lactams; the goal is to keep the drug level above the MIC for a certain
percentage of the dosing interval, rather than just relying on a high peak.
Q3: You are comparing two drugs in the same class used for hypertension. Drug A
requires a dose of 10mg to achieve the desired effect, while Drug B requires 100mg.
Which term best describes this difference?
, A. Drug A has higher efficacy than Drug B.
B. Drug B has higher potency than Drug A.
C. Drug A has higher potency than Drug B.
D. Drug B has a better therapeutic index.
Correct Answer: C
Rationale: The best answer is C because potency refers to the amount of drug needed
to produce an effect; since Drug A needs a lower dose to achieve the same effect, it is
more potent, though both may have equal efficacy (max effect).
Q4: A patient is taking a drug that is a "competitive agonist" at a receptor. If the patient
takes an overdose of this drug, what is the most appropriate pharmacological
intervention?
A. Administer a non-competitive antagonist to permanently block the receptor.
B. Administer a competitive antagonist to compete for the receptor site.
C. Increase the dose of the agonist to saturate all receptors.
D. Administer an inducer of the enzyme that metabolizes the drug.
Correct Answer: B
Rationale: In practice, you would administer a competitive antagonist because it
competes with the agonist for the receptor site; as the antagonist concentration rises, it
displaces the agonist, reversing the effect.
Q5: Which scenario best describes the concept of "first-pass effect"?
A. A drug injected intravenously bypasses the liver initially.
B. An orally administered drug is metabolized by the liver before reaching systemic
circulation, reducing bioavailability.
C. A drug is distributed to high-blood-flow organs like the brain and heart first.
D. A drug is excreted by the kidneys before it can be absorbed in the stomach.
Correct Answer: B
Rationale: The best answer is B because the first-pass effect specifically refers to the
metabolism of an oral drug by the liver (via the portal vein) before it enters the general
circulation, significantly lowering the amount of active drug available.
Q6: A patient with a history of angina is prescribed a nitroglycerin patch. What is the
primary mechanism of action that leads to therapeutic vasodilation?
A. Blockade of calcium channels in vascular smooth muscle.
B. Release of nitric oxide (NO), which increases cGMP and relaxes smooth muscle.
C. Inhibition of the conversion of Angiotensin I to Angiotensin II.
D. Direct stimulation of beta-2 receptors in the bronchioles.
Correct Answer: B
